Suven Life Sciences announces positive topline results from Phase-2 PoC signal detection open label study of Ropanicant
The primary objective was to evaluate safety and tolerability of Ropanicant in patients with MDD
The primary objective was to evaluate safety and tolerability of Ropanicant in patients with MDD
Both the products are Gadolinium based Magnetic Resonance Imaging (MRI) contrast agents and will be the first set of contrast agent products in Zydus’ injectable portfolio for the US market
Lasa Supergenerics Limited has been granted patent for an invention “Processes for Preparation and Purification of 5-Chloro-2-Nitroaniline
Secretary Vaidya Rajesh Kotecha has urged senior officials to strive for the successful attainment of targets during the campaign
ALS patients experience neuroinflammation and rapid neurodegeneration
The trial met its primary and secondary endpoints demonstrating that administration of a 3-dose regimen of GARDASIL 9
Phase 3 clinical trial designed to evaluate the safety and efficacy of tivozanib in combination with nivolumab
TTP Group is a leading engineering firm specializing in biotech and pharmaceutical industry
Presidential Symposium for NIAGARA will highlight practice-changing impact of a perioperative Imfinzi-based regimen in bladder cancer
eGenesis is pioneering a genome engineering-based approach in the development of safe and effective transplantable organs to end the global organ shortage
Subscribe To Our Newsletter & Stay Updated